1. Home
  2. CBFV vs SGMT Comparison

CBFV vs SGMT Comparison

Compare CBFV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CB Financial Services Inc.

CBFV

CB Financial Services Inc.

HOLD

Current Price

$37.66

Market Cap

193.1M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.42

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBFV
SGMT
Founded
1901
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
193.1M
169.4M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
CBFV
SGMT
Price
$37.66
$7.42
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$38.00
$26.13
AVG Volume (30 Days)
6.6K
1.3M
Earning Date
04-22-2026
05-14-2026
Dividend Yield
3.12%
N/A
EPS Growth
N/A
N/A
EPS
0.73
N/A
Revenue
$43,557,000.00
$2,000,000.00
Revenue This Year
$48.93
N/A
Revenue Next Year
$7.97
N/A
P/E Ratio
$51.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.49
$4.50
52 Week High
$38.86
$11.41

Technical Indicators

Market Signals
Indicator
CBFV
SGMT
Relative Strength Index (RSI) 50.99 54.97
Support Level $34.06 $7.09
Resistance Level $37.60 $7.95
Average True Range (ATR) 0.81 0.45
MACD -0.07 0.03
Stochastic Oscillator 49.86 57.48

Price Performance

Historical Comparison
CBFV
SGMT

About CBFV CB Financial Services Inc.

CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: